Difficult to convince payers to pay for alcohol pill
Sales of Lundbeck’s new drugs are still rising, while things look significantly worse for the company's pill to combat alcohol abuse, Selincro. But Lundbeck’s CFO eyes opportunities, especially in France.
BY BENJAMIN WERNER CHRISTENSEN
Sales from Lundbeck’s portfolio of new drugs, which includes Xenazine, Sabril, Sycrest, Lexapro in Japan, Onfi, Treanda, Selincro, Abilify Maintena, Brintellix and Northera, is showing progress, collectively speaking. But there are still challenges, especially in connection with the group’s drug to treat alcohol-dependence, Selincro.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck’s alcohol pill hits speed bump
For abonnenter
Lundbeck CFO: I can’t complain
For abonnenter
